[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K: [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases]. Hinyokika Kiyo; 2007 Jul;53(7):489-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1 was a 76-year-old man with loss of appetite and body weight and neck lymphadenopathies.
  • Whole body computed tomography (CT) revealed prostatic swelling, pancreatic mass, para-aortic lymphadenopathies, and multiple lung nodules.
  • Elevation of tumor markers (prostate specific antigen [PSA, 1,760 ng/ml] and neuron-specific enolase [NSE, 88 ng/ml]) was noted.
  • Cytotoxic chemotherapy was not possible because of his poor performance state and renal dysfunction.
  • The patient died three months after the diagnosis.
  • Treatment of combined SCC and adenocarcinoma of prostate poses a dilemma.
  • The opposite situation would be expected with systemic chemotherapy.
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male. Phosphopyruvate Hydratase / blood. Prostate-Specific Antigen / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702184.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


2. Bell JP, Mosfer SI, Lang D, Donaldson F, Lewis MJ: Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol Heart Circ Physiol; 2001 Oct;281(4):H1704-10
Hazardous Substances Data Bank. QUINAPRIL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs.
  • A possible role for endothelial dysfunction in this condition was investigated in a Dunkin-Hartley guinea pig aortic-banded pressure overload-induced model of LVH.
  • Aortic banding produced significant elevation of fore- and hindlimb blood pressure (BP), heart-to-body weight ratios, plasma angiotensin II (ANG II), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-alpha) levels, and coronary microvascular endothelial cell (CMEC) NAD(P)H-dependent superoxide (O) production, and a significant decrease in basal and stimulated CMEC cGMP levels.
  • Treatment of aortic-banded animals with the angiotensin-converting enzyme inhibitor quinapril and the antioxidant vitamin C, either alone or in combination, did not affect BP but caused a significant inhibition of the increases in the heart-to-body weight ratio, ANG II, ET-1, and TNF-alpha levels, and O production and restored cGMP responses to levels comparable with sham-operated animals.
  • [MeSH-major] Ascorbic Acid / therapeutic use. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiopathology. Hypertrophy, Left Ventricular / drug therapy. Isoquinolines / therapeutic use. Tetrahydroisoquinolines
  • [MeSH-minor] Animals. Aortic Valve Stenosis / complications. Aortic Valve Stenosis / physiopathology. Blood Pressure. Coronary Vessels / metabolism. Coronary Vessels / pathology. Guinea Pigs. Hypertension / complications. Hypertension / etiology. Hypertension / physiopathology. Male. NAD / physiology. NADP / physiology. Superoxides / metabolism

  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11557561.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 0U46U6E8UK / NAD; 11062-77-4 / Superoxides; 53-59-8 / NADP; PQ6CK8PD0R / Ascorbic Acid; RJ84Y44811 / quinapril
  •  go-up   go-down


3. Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B: Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation; 2008 Jan 22;117(3):421-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have shown previously that the dithiol compound alpha-lipoic acid (LA) exerts antiinflammatory effects by inhibiting tumor necrosis factor-alpha- and lipopolysaccharide-induced endothelial and monocyte activation in vitro and lipopolysaccharide-induced acute inflammatory responses in vivo.
  • METHODS AND RESULTS: Four-week-old female apoE-/- mice (n=20 per group) or apoE/low-density lipoprotein receptor-deficient mice (n=21 per group) were fed for 10 weeks a Western-type chow diet containing 15% fat and 0.125% cholesterol without or with 0.2% (wt/wt) R,S-LA or a normal chow diet containing 4% fat without or with 0.2% (wt/wt) R-LA, respectively.
  • Supplementation with LA significantly reduced atherosclerotic lesion formation in the aortic sinus of both mouse models by approximately 20% and in the aortic arch and thoracic aorta of apoE-/- and apoE/low-density lipoprotein receptor-deficient mice by approximately 55% and 40%, respectively.
  • This strong antiatherogenic effect of LA was associated with almost 40% less body weight gain and lower serum and very low-density lipoprotein levels of triglycerides but not cholesterol.
  • In addition, LA supplementation reduced aortic expression of adhesion molecules and proinflammatory cytokines and aortic macrophage accumulation.
  • These antiinflammatory effects of LA were more pronounced in the aortic arch and the thoracic aorta than in the aortic sinus, reflecting the corresponding reductions in atherosclerosis.
  • LA may be a useful adjunct in the prevention and treatment of atherosclerotic vascular diseases.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158360.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL079382; United States / NCCIH NIH HHS / AT / AT002034; United States / NHLBI NIH HHS / HL / HL60886; United States / NIEHS NIH HHS / ES / ES11542; United States / NHLBI NIH HHS / HL / HL079382
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Receptors, LDL; 0 / Triglycerides; 73Y7P0K73Y / Thioctic Acid; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


Advertisement
4. Seo S, Miki A, Kitai T, Ino K, Higashiyama H, Ukikusa M: [A case of gastric cancer with abdominal para-aortic lymph node metastases responding to TS-1 + CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1171-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with abdominal para-aortic lymph node metastases responding to TS-1 + CDDP neoadjuvant chemotherapy].
  • The patient was a 54-year-old woman with extremely advanced gastric cancer of type 3.
  • A CT scan of the abdomen showed enlargement of many huge abdominal para-aortic lymph nodes.
  • Combined chemotherapy of TS-1 and CDDP was planned in order to reduce the tumor.
  • TS-1 (100 mg/body/day) was administered for 21 days followed by 14 days rest as one course.
  • CDDP (96 mg/body) was administered 8 days after the start of TS-1.
  • After 2 courses of treatment, a CT scan showed complete disappearance of lymph node metastasis, and no high grade toxicities.
  • Therefore, one month after the completion of the chemotherapy, total gastrectomy and D2 lymph node dissection were performed.
  • Neoadjuvant chemotherapy with TS-1 and CDDP is so effective that can it be adapted for advanced gastric cancer with para-aortic lymph node enlargement for downstaging.
  • [MeSH-major] Lymphatic Metastasis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aorta, Abdominal. Cisplatin / administration & dosage. Drug Combinations. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121923.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Nozawa H, Sekikawa T, Tsukui H, Kina S, Kawahara T, Ono K, Kishida Y, Yakumaru K, Kagami H: Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case. Surg Today; 2001;31(4):340-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
  • We report herein a rare case with advanced gastric cancer combined with group 4 lymph node and lung metastases that responded remarkably to neoadjuvant chemotherapy.
  • A 65-year-old man was found to have a well-differentiated type 3 gastric cancer that invaded the duodenum locally and was accompanied with Virchow's, para-aortic lymph nodes, and multiple lung metastases based on physical, endoscopic, and radiological examinations.
  • Prior to surgery, he was treated with 5-fluorouracil (5-FU; 500mg/body per day) and low-dose cisplatinum (CDDP; 10mg/body per day) as neoadjuvant chemotherapy for 6 weeks.
  • Four weeks after the completion of neoadjuvant chemotherapy, a distal gastrectomy was performed, and a histopathological examination of the resected specimen showed a grade 2 response to chemotherapy.
  • Immunohistochemically, the thymidylate synthase expression level was very low in the tumor tissues, which might account for the good response to the combination chemotherapy with 5-FU and CDDP observed in the present case.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321346.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Mizutani S, Inada T, Fukutomi K, Igarashi S, Ogata Y: [A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation]. Gan To Kagaku Ryoho; 2000 Aug;27(9):1433-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
  • A 63-year-old male patient with type 3 advanced gastric cancer was referred to our hospital.
  • Preoperative examination by CT-scan revealed swollen para-aortic lymph nodes and cancer invasion to the pancreas.
  • The patient was treated pre-operatively with intravenous 5-FU, 500 mg/body/day, continuous infusion for 1 week.
  • Immediately after the chemotherapy, the patient underwent total gastrectomy, splenctomy, left-adrenectomy and resection of the body and tail of the pancreas, along with para-aortic lymph node dissection.
  • Microscopic examination revealed that the tumor was a moderately differentiated tubular adenocarcinoma, which displayed invasion to the pancreas with lymph node metastasis up to the level 3 lymph node.
  • Histologically, the effect of preoperative chemotherapy showed a grade 2 effect on the main tumor, but a grade 3 chemotherapeutic effect was observed at the para-aortic lymph nodes.
  • In this case, it is considered that the preoperative chemotherapy by 5-FU and potentially curative radical operation yielded a good outcome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Gastrectomy. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aorta. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology. Preoperative Care. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969602.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Kim JS, Kim JS, Kim SY, Kim Ki, Cho MJ: Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1247-53
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
  • PURPOSE: To evaluate efficacy, toxicity, and patterns of relapse in patients treated with hyperfractionated radiotherapy (HFRT) with concurrent chemotherapy for para-aortic lymph node (PALN) recurrence of cervical carcinoma.
  • METHODS AND MATERIALS: Between September 1997 and October 2000, 12 cervical carcinoma patients with isolated PALN recurrence who had previously received radical or postoperative radiotherapy were treated with HFRT and concurrent chemotherapy.
  • The radiation field encompassed the gross recurrent PALN with the superior margin at the upper end of the T12 body and the inferior margin between L5 and S1.
  • The fractionated dose was 1.2 Gy in 2 daily fractions, and the median total dose was 60 Gy.
  • The weekly concurrent chemotherapy consisted of paclitaxel in 11 patients and cisplatin in 1.
  • The median number of cycles of chemotherapy was 5.
  • RESULTS: The latent period to PALN recurrence from the time of initial treatment for all patients ranged from 2 to 92 months (median: 12 months).
  • One month after treatment, the clinical tumor response evaluated was complete in 33% (4/12) and partial in 67% (8/12).
  • The latent period to PALN recurrence was the only significant prognostic factor; the median survival of patients who relapsed in < or =24 months from the initial treatment of cervical carcinoma was 13 months vs. 45 months for those relapsed at >24 months (p = 0.026).
  • Grade 3-4 hematologic toxicity developed in 2 patients.
  • Subsequent distant metastases after PALN treatment developed in 58% (7/12).
  • CONCLUSION: HFRT of 60 Gy to PALN with concurrent chemotherapy could be regarded as an effective treatment modality without significant acute or late toxicity.
  • Patients with a latent period >24 months until PALN recurrence had a more favorable survival rate than those with a latent period </=24 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brachytherapy. Carcinoma, Squamous Cell / secondary. Cisplatin / therapeutic use. Lymphatic Irradiation. Lymphatic Metastasis / radiotherapy. Paclitaxel / therapeutic use. Radiotherapy, High-Energy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / secondary. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Hematologic Diseases / etiology. Humans. Hysterectomy. Life Tables. Middle Aged. Nausea / etiology. Neoplasm Metastasis. Radiation Injuries / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654434.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 29
  •  go-up   go-down


8. Hataji K, Ami K, Nagahama T, Ohara T, Ganno H, Kawasaki N, Fukuda A, Ando M, Arai K, Tei S: [A case of unresectable cardiac gastric cancer patient who maintained a long-term QOL with chemotherapy and detention of metallic stent]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2290-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable cardiac gastric cancer patient who maintained a long-term QOL with chemotherapy and detention of metallic stent].
  • He visited our hospital for dysphagia, abdominal distention and body weight loss.
  • He was underwent gastro-endoscopy and made a diagnosis of the advanced cardiac gastric cancer.
  • Furthermore, computed tomography was performed and detected multiple liver and spleen, para-aortic lymph-node metastases and the ascites (suspected for dissemination).
  • Therefore, we performed an abdominal puncture to remove the ascites and combination chemotherapy with S-1 and docetaxel.
  • The combination therapy was effective.
  • The main tumor and multiple metastatic lesions were reduced.
  • But after six months, a tumor marker was increased.
  • The anticancer drug was changed to S-1 and CDDP.
  • After eight months from the first-line chemotherapy started, the stenosis was appeared at esophago-gastric junction.
  • After eleven months from the first-line chemotherapy started, he was died of increased liver metastases and peritonitis carcinomatousa.
  • [MeSH-major] Cardia. Quality of Life. Stents. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037399.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Oshima N, Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Sugisawa N, Taki Y, Motegi Y, Boku N, Sasaki K, Terashima M: [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP]. Gan To Kagaku Ryoho; 2010 Apr;37(4):697-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP].
  • A 59-year-old male was found to have advanced gastric cancer with multiple lymph node metastasis including para-aortic lymph nodes(cT3, cN3, cM0, cH0, cP0, cStage IV).
  • Since curative surgery was deemed not feasible, we tried neoadjuvant chemotherapy expecting downstaging of the tumor.
  • S-1(120 mg/body)was orally administered for three weeks followed by one week rest, and CDDP(60 mg/m2)was administered on day 8.
  • Three courses of treatment resulted in a marked shrinkage of the primary lesion and a reduction of lymph nodes.
  • Laparotomy revealed neither ascites nor peritoneal dissemination, and he underwent total gastrectomy, splenectomy and D2+para-aortic lymph node dissection with curative intent.
  • The histological diagnosis revealed complete disappearance of cancer cells in the primary lesion of the stomach and lymph nodes, confirming a pathological complete response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414029.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M: [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1761-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy].
  • The lesion was judged to be P1, SE, H0, N2 and Stage IV and the patient was managed on a regular schedule as an outpatient.
  • A fiber optic examination of the sigmoid colon detected an ulcerous lesion with a hemorrhage at the anterior rectal wall.
  • Starting in October 2004, 100 mg/day of TS-1 was administered for 3 weeks; intravenous drip infusion of 100 mg/body of CDDP was conducted in the second week for a period of 24 hours.
  • After 3 courses of this regimen, a fiber optic examination of the colon conducted in February 2005 no longer detected the rectal tumor, leaving only a cicatrix.
  • Upon a CT examination, the para-aortic lymph nodes that had been enlarged were notably reduced in size and an improvement was eminent in the hypertrophic rectal wall.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cholecystectomy. Cisplatin / administration & dosage. Constriction, Pathologic. Drug Combinations. Female. Gastrectomy. Humans. Oxonic Acid / administration & dosage. Pancreatectomy. Pyridines / administration & dosage. Splenectomy. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Ehrhart N, Ehrhart EJ, Willis J, Sisson D, Constable P, Greenfield C, Manfra-Maretta S, Hintermeister J: Analysis of factors affecting survival in dogs with aortic body tumors. Vet Surg; 2002 Jan-Feb;31(1):44-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors affecting survival in dogs with aortic body tumors.
  • OBJECTIVE: To evaluate the effect of perioperative and operative variables on survival time in dogs with aortic body tumors.
  • SAMPLE POPULATION: Twenty-four client-owned dogs with histologically confirmed aortic body tumor.
  • METHODS: Seventy-eight patient records of dogs seen at the University of Illinois Veterinary Teaching Hospital between 1989 and 1999 with a diagnosis of a heart-base mass were reviewed.
  • Dogs without histologic conformation of an aortic body tumor were excluded.
  • Age; sex; breed; the presence of pleural effusion, pericardial effusion, or abdominal effusion; evidence of cardiac arrhythmias; evidence of distant metastasis; treatment with pericardectomy; treatment with chemotherapy; and time from diagnosis until euthanasia or death were recorded on a spreadsheet.
  • Cox proportional-hazard ratios were used to calculate the relationship of risk variables to survival time.
  • Median survival time was determined using life-table analysis.
  • The median age of dogs with aortic body tumors was 9 years.
  • Fourteen dogs had a pericardectomy at the time of the biopsy procedure.
  • Of all factors analyzed, only treatment with pericardectomy had a significant influence on survival (P =.0029).
  • This finding was independent of the presence or absence of pericardial effusion at the time of surgery.
  • CLINICAL RELEVANCE: Dogs that are diagnosed with aortic body tumors may benefit from a pericardectomy at the time of surgical biopsy.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by The American College of Veterinary Surgeons
  • (PMID = 11778166.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Shimizu J, Ikeda C, Arano Y, Adachi I, Morishita M, Yamaguchi S, Ishikawa N, Watanabe G, Minato H: Advanced lung cancer invading the left atrium, treated with pneumonectomy combined with left atrium resection under cardiopulmonary bypass. Ann Thorac Cardiovasc Surg; 2010 Aug;16(4):286-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 68-year-old man presented with a chief complaint being a cough.
  • Chest computed tomography (CT) scans demonstrated a giant mass of the left lower lobe, 14 × 12 cm in size, which appeared to have invaded the left atrium (LA).
  • The patient underwent left pneumonectomy combined with LA resection using cardiopulmonary bypass (CPB), without aortic clamping, through left posterolateral thoracotomy under hypothermia (32 °C).
  • The tumor-invaded LA was resected in a 3.5 × 3.0 cm area, with vascular clamping, and the stump was closed with 3-0 Prolene sutures.
  • The surgical margin was free of tumor cells, and the duration of CPB was 28 minutes.
  • His postoperative course was uneventful, and he received 2 courses of adjuvant chemotherapy.
  • If CPB is used, the tension of the LA is removed by blood extraction into the bypass, and bradycardia is induced by a reduction of body temperature, probably reducing the risk of clamp dislocation.
  • [MeSH-minor] Aged. Cardiac Surgical Procedures. Cardiopulmonary Bypass. Heart Atria / pathology. Humans. Male. Neoplasm Invasiveness. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057449.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Koo DJ, Yoo P, Cioffi WG, Bland KI, Chaudry IH, Wang P: Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res; 2000 Jun 1;91(1):70-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hour after CLP, PTX (50 mg/kg body wt) or vehicle (normal saline) was infused intravenously over 90 min.
  • Rat ADM (10(-7) M) was applied, and the percentage of ADM-induced relaxation in the aortic rings and resistance vessels in the small intestine was determined.
  • In addition, plasma ADM was determined by radioimmunoassay and tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6 levels were measured by enzyme-linked immunosorbent assay.
  • RESULTS: The percentage of ADM-induced vascular relaxation in the aortic rings and resistance vessels of the isolated gut was significantly reduced 20 h after CLP.
  • [MeSH-major] Aorta / immunology. Cytokines / blood. Pentoxifylline / pharmacology. Peptides / pharmacology. Phosphodiesterase Inhibitors / pharmacology. Sepsis / drug therapy. Vasodilator Agents / pharmacology
  • [MeSH-minor] Adrenomedullin. Animals. Cecum / injuries. Cecum / surgery. Interleukin-1 / blood. Interleukin-1 / immunology. Interleukin-6 / blood. Interleukin-6 / immunology. Ligation. Male. Organ Culture Techniques. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha / immunology. Tumor Necrosis Factor-alpha / metabolism. Vasodilation / drug effects. Wounds, Stab

  • MedlinePlus Health Information. consumer health - Sepsis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10816353.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / KO2AI01461; United States / NIGMS NIH HHS / GM / R01GM57468
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Peptides; 0 / Phosphodiesterase Inhibitors; 0 / Tumor Necrosis Factor-alpha; 0 / Vasodilator Agents; 148498-78-6 / Adrenomedullin; SD6QCT3TSU / Pentoxifylline
  •  go-up   go-down


14. Zhao H, Liao Y, Minamino T, Asano Y, Asakura M, Kim J, Asanuma H, Takashima S, Hori M, Kitakaze M: Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res; 2008 Oct;31(10):1977-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to investigate whether pravastatin can inhibit cardiac remodeling and ameliorate endoplasmic reticulum (ER) stress caused by pressure overload or tumor necrosis factor alpha (TNFalpha).
  • Either pravastatin (5 mg/kg/d) or vehicle alone was orally administered to male C57BL/6J mice from day 2 after a transverse aortic constriction (TAC) was performed.
  • Four weeks after TAC, pravastatin treatment significantly reduced heart/body weight and lung/body weight ratios and increased left ventricular (LV) fractional shortening compared with the TAC alone.
  • Markers of ER stress, such as increases in ER chaperone and C/EBP homologous protein (CHOP) expression and enhanced phosphorylation of anti-phospho-eukaryotic initiation factor 2alpha (eIF2alpha), were observed in the hearts of TAC mice, while pravastatin treatment significantly blunted these changes.
  • [MeSH-major] Endoplasmic Reticulum / drug effects. Heart Failure / drug therapy. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Pravastatin / pharmacology. Stress, Physiological / drug effects. Ventricular Remodeling / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cardiomegaly / drug therapy. Cardiomegaly / metabolism. Cardiomegaly / pathology. Fibrosis. Lipopolysaccharides / pharmacology. Male. Mice. Mice, Inbred C57BL. Molecular Chaperones / metabolism. Myocardium / metabolism. Myocardium / pathology. Myocytes, Cardiac / metabolism. Myocytes, Cardiac / pathology. Signal Transduction / drug effects. Tumor Necrosis Factor-alpha / metabolism. Ventricular Pressure

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015605.001).
  • [ISSN] 0916-9636
  • [Journal-full-title] Hypertension research : official journal of the Japanese Society of Hypertension
  • [ISO-abbreviation] Hypertens. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Lipopolysaccharides; 0 / Molecular Chaperones; 0 / Tumor Necrosis Factor-alpha; KXO2KT9N0G / Pravastatin
  •  go-up   go-down


15. Santillan A, Bristow RE: Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol; 2006 Feb;3(2):108-12; quiz 1 p following 112
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During her initial admission, the patient improved to some degree and was discharged with a possible diagnosis of viral meningitis.
  • INVESTIGATIONS: General physical and gynecological examinations, MRI of the brain, lumbar punctures, electroencephalogram, transvaginal ultrasound, mammogram, tumor markers, anti-neuronal antibodies, colonoscopy, whole-body positron emission tomography scan, laparoscopy and biopsies.
  • DIAGNOSIS: Stage IIIC endometrioid adenocarcinoma of the ovary with paraneoplastic cerebellar degeneration.
  • MANAGEMENT: Tumor cytoreduction, plasmapheresis, total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic and para-aortic lymph-node dissection, total omentectomy, carboplatin and paclitaxel chemotherapy, rehabilitation, and speech therapy.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Ovarian Neoplasms / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


16. Hamsa TP, Kuttan G: Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol; 2010 Dec 15;649(1-3):64-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
  • Harmine is a beta-carboline alkaloid present in medicinal plants such as Peganum harmala that have been used as folk medicine in anticancer therapy.
  • Intraperitoneal administration of harmine at 10 mg/kg body weight significantly decreased tumour directed capillary formation.
  • A drastic elevation in serum pro-angiogenic factors such as vascular endothelial growth factor (VEGF), nitric oxide (NO) and pro-inflammatory cytokines in angiogenesis induced animals was significantly decreased by harmine treatment.
  • At the same time harmine increased anti-tumour factors like interleukin-2 (IL-2) and tissue inhibitor metalloprotease (TIMP).
  • Moreover nuclear factor (NF)-κB and other transcription factors like CREB, ATF-2 involved in tumour development and angiogenesis were also inhibited by harmine.
  • Direct treatment of the harmine also inhibited microvessel outgrowth from the rat aortic ring.
  • Production of other factors by tumour cells which are involved in angiogenesis like cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS) and matrix metalloproteases (MMPs) were also decrease by the treatment with harmine.
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. In Vitro Techniques. Male. Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Melanoma, Experimental / metabolism. Mice. Mice, Inbred C57BL. Microvessels / drug effects. RNA, Messenger / metabolism. Rats. Vascular Endothelial Growth Factors / blood. Vascular Endothelial Growth Factors / genetics. Vascular Endothelial Growth Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20858484.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiogenic Proteins; 0 / Antineoplastic Agents, Phytogenic; 0 / Inflammation Mediators; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factors; 4FHH5G48T7 / Harmine
  •  go-up   go-down


17. Michigami S, Yada K, Morita M, Hibuse Y, Ogawa Y: [Advanced gastric cancer successfully treated by TS-1--case report]. Gan To Kagaku Ryoho; 2004 Jun;31(6):921-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old woman came to our hospital because of poor appetite, and careful examination revealed a Borrmann type 2 tumor on the posterior wall of the lower body of the stomach as well as enlarged para aortic-lymph nodes.
  • Surgery was performed in November 2000, but because the para-aortic lymph nodes were densely adherent to the aorta, it was impossible to dissect the lymph nodes from the wall (N3, Stage IV).
  • After one course of TS-1, the enlarged para-aortic lymph nodes were no longer seen on abdominal computed tomography (CT).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aorta, Abdominal / pathology. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Gastrectomy. Humans. Lymphatic Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222113.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 11
  •  go-up   go-down


18. Rais H, Elmansouri F, Belaabidia B, Essadki O, Oussehal A, Sarf I: [Paratesticular desmoplastic small round cell tumour: case report with literature review]. Cancer Radiother; 2010 Apr;14(2):111-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular desmoplastic small round cell tumour: case report with literature review].
  • They are usually intra-abdominal tumors affecting young people and have classically been associated with a bad prognosis.
  • However, in recent years there have been reports on desmoplastic small round cell tumors affecting other body regions, including the paratesticular area.
  • A computed tomography scan showed a para-aortic mass of 1cm.
  • Histological and immunohistochemical diagnosis confirmed a desmoplastic small round cell tumor.
  • The patient received chemotherapy.
  • Today, 6 months after diagnosis the patient remains well and free of disease.
  • We should include this lesion among the differential diagnosis of paratesticular tumors, mainly in children and adolescents.
  • [MeSH-minor] Adolescent. Adult. Cell Division. Child. Humans. Immunohistochemistry. Keratins / genetics. Male. Orchiectomy. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009. Published by Elsevier SAS.
  • (PMID = 20189431.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


19. Kadl A, Pontiller J, Exner M, Leitinger N: Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock; 2007 Nov;28(5):582-8
MedlinePlus Health Information. consumer health - Antioxidants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mice were challenged with sublethal doses (2 mg/kg body weight) of LPS, and the effects of intravenously administered bilirubin (40 mg/kg body weight) were assessed.
  • Bilirubin treatment improved the clinical score significantly at all time points assessed, attenuated weight loss, and improved LPS-induced anorexia.
  • Furthermore, bilirubin treatment inhibited LPS-induced leukocyte-endothelial interactions and leukocyte accumulation in various tissues.
  • Moreover, bilirubin inhibited LPS-induced expression of inflammatory genes in isolated cultured aortic endothelial cells and in bone marrow-derived macrophages.
  • These data show that single-dose administration of bilirubin attenuates tissue injury induced by endotoxin, and that bilirubin, in addition to its antioxidant effects, also exerts potent anti-inflammatory activity.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Antioxidants / pharmacology. Bilirubin / pharmacology. Endotoxemia / drug therapy
  • [MeSH-minor] Animals. Biliverdine / blood. Cell Adhesion Molecules / biosynthesis. Cell Communication / drug effects. Cells, Cultured. Disease Models, Animal. Endothelial Cells / metabolism. Endothelial Cells / pathology. Gene Expression Regulation / drug effects. Inflammation Mediators / metabolism. Interleukin-1beta / biosynthesis. Leukocytes / metabolism. Leukocytes / pathology. Lipopolysaccharides / toxicity. Lung / metabolism. Lung / pathology. Lung Injury. Macrophages / metabolism. Macrophages / pathology. Male. Mice. Mice, Inbred BALB C. Rats. Time Factors. Tumor Necrosis Factor-alpha / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577133.001).
  • [ISSN] 1073-2322
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Cell Adhesion Molecules; 0 / Inflammation Mediators; 0 / Interleukin-1beta; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha; O9MIA842K9 / Biliverdine; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


20. Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, Zheng S, Wang A, Zhang C, Chen L, Lei N: Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro. Cancer Biol Ther; 2009 Aug;8(15):1489-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro.
  • Additionally, VEGF-induced vessel sprouting of rat aortic ring was also inhibited by HS.
  • The protein level secreted by B16F10 cells of MMP-2,-9 and VEGF were decreased by HS treatment.
  • In vivo, a tumor growth inhibition study was carried out using mice bearing B16F10 cells model of metastasis, no matter experimental or spontaneous, showed that HS at 5.2, 11.6 and 26 mg/kg (weight of mice) could markedly decreased the metastatic tumors in mouse lung in a dose-dependent manner.
  • In CAM assay and Matrigel plug assay in vivo, HS (50 microg/egg and 100 microg/egg) inhibited new blood vessel formation on the growing chick chorioallantoic membrane, and HS (5.2 and 26 mg/kg body weight) reduced the vessel density in Matrigel plugs implanted in mice.
  • [MeSH-major] Angiogenesis Inhibitors / isolation & purification. Antineoplastic Agents / pharmacology. Glycosaminoglycans / pharmacology. Holothuria / chemistry. Melanoma, Experimental / drug therapy. Neoplasm Invasiveness / prevention & control
  • [MeSH-minor] Animals. Aorta / drug effects. Cell Line / cytology. Cell Line / drug effects. Cell Line, Tumor / cytology. Cell Line, Tumor / drug effects. Cell Movement / drug effects. Drug Screening Assays, Antitumor. Endothelial Cells / cytology. Endothelial Cells / drug effects. Humans. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Mice. Mice, Inbred C57BL. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Rats. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483477.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Glycosaminoglycans; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


21. Cypiene A, Laucevicius A, Venalis A, Ryliskyte L, Dadoniene J, Petrulioniene Z, Kovaite M, Laskova V, Gintautas J: Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc; 2007;50:119-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this clinical work was to determine the modification of carotid-radial pulse wave velocity (PWV) and aortic augmentation index (AIx) in young-aged RA patients and the influence of treatment with anti-TNF-alpha (infliximab) on these measures.
  • Analysis (Mann-Whitney test) in 15 RA patients revealed lowering of PWV (p = 0.004) under infliximab therapy with no change in AIx (p = 0.573), suggesting the improvement of arterial wall function by anti-TNF-alpha therapy.
  • PWV appears to be a less sensitive marker for the detection of enhanced development of arterial stiffness in relatively young-aged RA patients.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Arteries / physiology. Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / pathology. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Body Mass Index. Carotid Arteries / pathology. Elasticity. Female. Humans. Infliximab. Male. Manometry. Risk Factors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18605247.001).
  • [ISSN] 0083-8969
  • [Journal-full-title] Proceedings of the Western Pharmacology Society
  • [ISO-abbreviation] Proc. West. Pharmacol. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


22. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL: Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem; 2006 Apr;285(1-2):35-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LDLr deficient mice fed HF diet and simultaneously treated with fenofibrate (100 mg/kg body weight) prevented development of obesity, lowered serum triglycerides and cholesterol, improved insulin sensitivity, and prevented accumulation of lipids in the aorta.
  • The reductions in body weight were associated with elevation of hepatic uncoupling protein 2 (UCP2) mRNA, a concomitant increase in the ketone body formation, and improved insulin sensitivity associated with tumor necrosis factor-alpha reductions and phosphoenol pyruvate carboxykinase down-regulation.
  • Fenofibrate-mediated hypolipidemic effects together with improved insulin sensitivity and loss of adiposity led to the reductions in the aortic lipid deposition by inhibiting early stages of atherosclerosis possibly via vascular cell adhesion molecule-1 (VCAM-1) modulation.
  • These results suggest that potent PPAR-alpha activators may be useful in the treatment of syndrome X.
  • [MeSH-major] Adiposity / drug effects. Coronary Artery Disease / drug therapy. Fenofibrate / pharmacology. Insulin Resistance. PPAR alpha / physiology. Receptors, LDL / deficiency
  • [MeSH-minor] Animals. Aorta / pathology. Diet, Atherogenic. Energy Metabolism / drug effects. Gluconeogenesis / drug effects. Hypercholesterolemia / drug therapy. Hypertriglyceridemia / drug therapy. Insulin / metabolism. Leptin / metabolism. Ligands. Lipid Metabolism / drug effects. Lipids / blood. Lipogenesis / drug effects. Lipogenesis / genetics. Liver / drug effects. Liver / secretion. Male. Metabolic Syndrome X / drug therapy. Mice. Mice, Inbred C57BL. Obesity / drug therapy. Obesity / prevention & control. Triglycerides / metabolism. Weight Gain / drug effects

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. Fenofibrate .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacotherapy. 2001 Sep;21(9):1082-99 [11560198.001]
  • [Cites] Atherosclerosis. 2003 Nov;171(1):49-55 [14642405.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):861-6 [9516220.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):585-91 [15618549.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38870-6 [11481335.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):317-29 [12790802.001]
  • [Cites] Hypertension. 2001 Apr;37(4):1053-9 [11304502.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):905-10 [11289345.001]
  • [Cites] J Nutr. 2004 May;134(5):1013-9 [15113938.001]
  • [Cites] Endocrinology. 2001 Oct;142(10 ):4189-94 [11564673.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):523-31 [10953027.001]
  • [Cites] FEBS Lett. 2001 Feb 23;491(1-2):154-8 [11226439.001]
  • [Cites] Recent Prog Horm Res. 2004;59:207-23 [14749503.001]
  • [Cites] Biochim Biophys Acta. 1992 May 8;1125(3):251-61 [1596514.001]
  • [Cites] Metabolism. 2004 May;53(5):607-13 [15131765.001]
  • [Cites] Diabetes. 2003 Sep;52(9):2249-59 [12941763.001]
  • [Cites] Biochim Biophys Acta. 1991 Oct 15;1086(1):29-43 [1683257.001]
  • [Cites] Annu Rev Med. 2005;56:45-62 [15660501.001]
  • [Cites] Inflamm Res. 2005 Feb;54(2):74-81 [15750714.001]
  • [Cites] Trends Cardiovasc Med. 2001 Jul;11(5):170-6 [11597827.001]
  • [Cites] Physiol Rev. 1995 Jul;75(3):473-86 [7624391.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16638-42 [10828060.001]
  • [Cites] Cardiovasc Res. 2002 Sep;55(4):820-9 [12176131.001]
  • [Cites] J Lipid Res. 1998 Jan;39(1):17-30 [9469582.001]
  • [Cites] Biochem J. 2003 Aug 1;373(Pt 3):941-7 [12713444.001]
  • [Cites] J Clin Invest. 1992 Nov;90(5):1889-900 [1430212.001]
  • [Cites] Diabetes. 2002 Feb;51(2):276-83 [11812733.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Sep;4(9):1088-94 [14582453.001]
  • [Cites] Curr Opin Lipidol. 1998 Jun;9(3):231-6 [9645506.001]
  • [Cites] J Clin Invest. 2004 Dec;114(11):1564-76 [15578089.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21805-8 [10823815.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42 [15345516.001]
  • [Cites] Methods Mol Biol. 1998;86:103-12 [9664460.001]
  • [Cites] J Clin Invest. 2004 Dec;114(11):1666-75 [15578099.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E207-14 [11739102.001]
  • [Cites] Biochem J. 1994 Mar 1;298 ( Pt 2):409-14 [8135749.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8416-25 [10722675.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48051-7 [12377786.001]
  • [Cites] Science. 2002 May 31;296(5573):1703-6 [11988537.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33360-6 [9407129.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):23044-53 [11925428.001]
  • [Cites] Diabetes. 2001 Feb;50(2):411-7 [11272155.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 18;43(4):585-91 [14975468.001]
  • [Cites] J Lipid Res. 1995 Dec;36(12):2541-51 [8847480.001]
  • [Cites] J Lipid Res. 2004 Aug;45(8):1475-81 [15145981.001]
  • [Cites] Nature. 1998 Jun 25;393(6687):790-3 [9655393.001]
  • [Cites] Curr Atheroscler Rep. 2004 Mar;6(2):148-57 [15023300.001]
  • [Cites] Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27 [14984018.001]
  • [Cites] Mol Cell Biochem. 1999 Dec;202(1-2):37-46 [10705993.001]
  • [Cites] Am Heart J. 2004 Aug;148(2):211-21 [15308990.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1255-62 [11375415.001]
  • [Cites] Diabetes. 2001 Dec;50(12):2809-14 [11723064.001]
  • [Cites] Metabolism. 2001 Nov;50(11):1294-300 [11699047.001]
  • [Cites] J Lipid Res. 2004 Mar;45(3):592-601 [14999041.001]
  • [Cites] J Cardiovasc Risk. 2000 Oct;7(5):339-45 [11143764.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2409-15 [7738205.001]
  • (PMID = 16477380.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Insulin; 0 / Leptin; 0 / Ligands; 0 / Lipids; 0 / PPAR alpha; 0 / Receptors, LDL; 0 / Triglycerides; U202363UOS / Fenofibrate
  •  go-up   go-down


23. Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W: Cytochrome P450 3A4 activity after surgical stress. Crit Care Med; 2003 May;31(5):1338-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the relationship between the acute inflammatory response after surgical trauma and changes in hepatic cytochrome P450 3A4 activity, compare changes in cytochrome P450 3A4 activity after procedures with varying degrees of surgical stress, and to explore the time course of any potential drug-cytokine interaction after surgery.
  • PATIENTS: A total of 16 patients scheduled for elective repair of an abdominal aortic aneurysm (n = 5), complete or partial colectomy (n = 6), or peripheral vascular surgery with graft (n = 5).
  • Abdominal aortic aneurysm and colectomy patients also had an ERMBT performed at discharge.
  • Blood samples were obtained before surgery, immediately after surgery, and 6, 24, 32, 48, and 72 hrs after surgery for determination of plasma concentrations of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha.
  • MEASUREMENTS AND MAIN RESULTS: ERMBT results significantly declined in all three surgical groups, with the lowest value at the time of the 72-hr study in all three groups.
  • Subjects with a peak interleukin-6 of >100 pg/mL had a significantly lower nadir ERMBT compared with subjects with a peak interleukin-6 of <100 pg/mL (35.5% +/- 5.2% vs. 74.7% +/- 5.1%, p <.001).
  • CONCLUSIONS: Acute inflammation after elective surgery was associated with a significant decline in cytochrome P450 3A4 activity, which is predictive of clinically important changes in the metabolism of commonly used drugs that are substrates for this enzyme.
  • [MeSH-minor] Acute Disease. Aged. Aortic Aneurysm, Abdominal / surgery. Blood Loss, Surgical / statistics & numerical data. Body Height. Body Weight. Breath Tests. Colectomy / adverse effects. Cytochrome P-450 CYP3A. Female. Fluid Therapy / statistics & numerical data. Humans. Inflammation. Interleukin-1 / blood. Interleukin-6 / blood. Linear Models. Male. Middle Aged. Peripheral Vascular Diseases / surgery. Predictive Value of Tests. Prospective Studies. Time Factors. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771600.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


24. Stein JP: Lymphadenectomy in bladder cancer: how high is "high enough"? Urol Oncol; 2006 Jul-Aug;24(4):349-55
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The role of a regional lymphadenectomy in the surgical treatment of high-grade, invasive transitional cell carcinoma of the bladder has evolved over the last several decades.
  • RESULTS: A growing body of evidence, spanning from early autopsy and cadaveric studies to recent retrospective series and multicenter prospective trials, suggests that an extended lymph node dissection (cephalad extent to include the common iliac arteries) may provide not only prognostic information but also provide a therapeutic benefit for both patients with lymph node-positive and lymph node-negative disease undergoing radical cystectomy for bladder cancer.
  • The need to extend the dissection higher to include the distal para-aortic and paracaval lymph nodes may be important in select individuals but remains more controversial.
  • The extent of the primary bladder tumor (p-stage), number of lymph nodes removed, the lymph node tumor burden (tumor volume), and lymph node density (number of lymph nodes involved/number of lymph nodes removed) are all important prognostic variables in patients undergoing cystectomy with pathologic evidence of lymph node metastases.
  • Systemic adjuvant chemotherapy remains a mainstay of treatment of patients with lymph node metastases.
  • When feasible, adjuvant chemotherapy is warranted in patients with positive nodal metastasis.

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818190.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Miyagi T, Nagasaki A, Shinzato O, Ohshima K, Takasu N: [Interdigitating dendritic cell sarcoma/tumor--a case report]. Gan To Kagaku Ryoho; 2007 Mar;34(3):469-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma/tumor--a case report].
  • We report an extremely rare case of interdigitating dendritic cell sarcoma/tumor (IDCS).
  • A 52-year-old man presented with a 2-week history of fever in January 2002.
  • Whole-body computerized tomography showed enlarged lymph nodes in mediastinal, right axillary, abdominal para-aortic, ileum, and inguinal regions.
  • Immunohistochemically, the tumor cells expressed S-100 protein, CD 68, and CD 45 RO.
  • These findings were compatible with the diagnosis of IDCS.
  • However, he developed fungal pneumonia and died of respiratory failure 1 month after the start of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells / pathology. Lymph Nodes / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Hepatomegaly / pathology. Humans. Male. Middle Aged. Prednisone / administration & dosage. Rare Diseases. Splenomegaly / pathology. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353646.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down






Advertisement